About 200 reports

  • 2.4.3 LYSOSOMAL STORAGE DISEASE
  • GENETIC DISORDERS, AFFECTED AREAS OF LSDS

LSDs are a family of over ## diverse diseases related by their molecular pathology.

  • Neurological Disorder
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • 5.3 MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES (DROC)

Over ## million American adults (## in ##) have at least one mental health condition.

  • Neurological Disorder
  • North America
  • United States
  • Market Size
  • Masimo Corporation
  • ELECTROENCEPHALOGRAPHY GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2015-2023) ($MN)

For single channel EEG recordings, three electrodes are needed one active, one reference and one ground. ##-channel device are implemented to perform tasks like EEG screening studies in case the neoplasm or cerebrovascular pathology, in suspected cerebral function

  • Neurological Disorder
  • World
  • Market Size
  • Compumedics Limited
  • Medtronic, Inc.

Laboratories performing genetic tests can be accredited through the Clinical Pathology Accreditation UK Ltd scheme.

  • Neurological Disorder
  • North America
  • United States
  • World
  • Forecast

While the exact disease pathology is not fully understood, it is known that the symptoms largely result from reduced levels of a neurotransmitter called dopamine in the brain.

  • Neurological Disorder
  • World
  • Boston Scientific Corporation
  • Cyberonics, Inc.
  • Jude Medical, Inc.
  • 12.1 BIBLIOGRAPHY

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE; ##(##): ##-##.

  • Neurological Disorder
  • United States
  • Forecast
  • Eisai Co., Ltd.
  • GW Pharmaceuticals plc
  • MARKET CHALLENGES

AD is one of the most common types of NDDs.

  • Neurological Disorder
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.

You can easily book an appointment with one online.

  • Neurological Disorder
  • World
  • Market Size
  • GlaxoSmithKline plc
  • Novartis AG

The company focuses on developing novel therapies for urological pathologies with a focus on uro-oncology.

  • Neurological Disorder
  • Allergan plc
  • Galderma S.A.
  • Ipsen S.A.
  • Merz Pharmaceuticals GmbH
  • 3.1 US Tardive Dyskinesia Market: An Analysis
  • US Tardive Dyskinesia Market by Number of Patients; 2016-2020 ('000)

However, due to unusual pathology related to tardive dyskinesia, the disease is underdiagnosed and represents a much larger population than is estimated.

  • Neurological Disorder
  • United States
  • Market Size
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.

Also, one molecule with unknown status and one terminated molecule have been identified.

  • Neurological Disorder
  • Asterias Biotherapeutics, Inc.
  • Athersys, Inc.
  • Celgene Corporation
  • Enlivex

Scale = ##-##, where ## is low impact, and ## is high impact.

  • Neurological Disorder
  • World
  • Market Size
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.
  • INTRODUCTION

Genet Test. 2002; ##(##):##- ## ##.

  • Mental Health
  • Neurological Disorder
  • Pathology
  • 5.1 BIBLIOGRAPHY

The American Journal of Pathology; ##(##): 2068-2076.

  • Neurological Disorder
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group
  • Sanofi S.A.
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market,

(Inactive) ## ## ## ## ## Bluebird bio, Inc. ## ## ## ## ## Asklepion Pharmaceuticals, LLC ## ## ## ## ## NUVISAN GmbH ## ## ## ## ## Nutra Pharma Corporation ## ## ## ## ## Nuo Therapeutics, Inc. ## ## ## ## ## Neuralgene

  • Neurological Disorder
  • World
  • Aldagen, Inc.
  • Asklepion Pharmaceuticals, LLC
  • Nutra Pharma Corporation
  • CAUSE OF THE DISEASE

EPILEPTIC SEIZURES ARE OBSERVED IN AUTOIMMUNE ENCEPHALOPATHIES INVOLVING AUTOANTIBODIES AND OTHER TYPES OF IMMUNE-RELATED PATHOLOGIES.

  • Neurological Disorder
  • Germany
  • Italy
  • Poland
  • Spain

Elekta achieved one milestone with zero helium boil-off technology.

  • Neurological Disorder
  • World
  • Covidien plc
  • Medtronic, Inc.
  • Nihon Kohden Corporation
  • 6.6 INCREASED KNOWLEDGE OF HD PATHOGENESIS
  • 3 Disease Overview

The American Journal of Pathology; ##(##): ##-##.

  • Neurological Disorder
  • United States
  • GlobalData's company
  • Huntington Study Group
  • Pfizer Inc.

Chapter ## ##-## Clinical Overview Chapter ## and intracranial hemorrhage is uncertain.

  • Neurological Disorder
  • United States
  • Forecast
  • GE Healthcare Limited
  • Stryker Corporation

It affects one in approximately ##, ## live births.

  • Neurological Disorder
  • Therapy
  • BioMarin Pharmaceutical
  • Lilly Endowment Inc.
  • PTC Therapeutics, Inc.
  • 3.4.1 SOURCES USED

Journal of Neurological Sciences; ##(##-##): ##-##.

  • Neurological Disorder
  • Japan
  • United States
  • World
  • Forecast

THE ALTERNATIVE COMPLEMENT PATHWAY MIGHT HAVE A ROLE IN MUSK MYASTHENIA, BUT OVERALL THE SIGNIFICANCE FOR PATHOLOGY REMAINS UNCERTAIN.

  • Neurological Disorder
  • Alexion Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • GlobalData's company
  • Roche Group
  • MOLECULAR DIAGNOSTIC TEST - MULTIPLE SCLEROSIS - PRODUCT STATUS
  • MOLECULAR DIAGNOSTIC TEST - MULTIPLE SCLEROSIS - PRODUCT DESCRIPTION

It develops therapeutics for nervous system pathologies involving human endogenous retroviruses.

  • Autoimmune Disease
  • Clinical Trial
  • Neurological Disorder
  • United States
  • Grifols, S.A.
  • parties expect the transaction to close mid-2016.
  • CSL LTD

It develops therapeutics for nervous system pathologies involving human endogenous retroviruses.

  • Neurological Disorder
  • Therapy
  • United States
  • World
  • Product Initiative

The molecules developed by Companies in Phase I, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Neurological Disorder
  • Therapy
  • United States
  • World
  • AndroScience Corporation, Inc
  • Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Product Development Milestones

This vector was confirmed to provide GAA expression and activity in target tissues, improved muscle pathology and a favorable immunogenicity profile.

  • Neurological Disorder
  • United States
  • World
  • Product Initiative
  • Amicus Therapeutics

The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Neurological Disorder
  • Therapy
  • United States
  • World
  • AndroScience Corporation, Inc
  • CLASSIFICATION OF PRIMARY AND SECONDARY TAUOPATHIES
  • 3.2.2 Pathological Classification

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no treatments approved in this therapy area and five tauopathies are attracting increasing attention from pharmaceutical...

  • Clinical Trial
  • Neurological Disorder
  • Therapy
  • United States
  • Company Operations
  • R&D Progress Research and Development Brief

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Neurological Disorder
  • United States
  • World
  • Product Initiative
  • Acceleron Pharma, Inc.
  • FEB 08, 2018: AUTISM, SCHIZOPHRENIA, BIPOLAR DISORDER SHARE MOLECULAR TRAITS, STUDY FINDS
  • JAN 30, 2017: UCLA WILL LEAD $21 MILLION, GRANT-FUNDED STUDY OF EPILEPSY AFTER TRAUMATIC BRAIN INJURIES

Psychiatric disorders, in contrast, are not defined by such pathology, but rather by behavior.

  • Cancer
  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • United States